FuzzyBot: Importing a new version from external source

2024-02-12T10:46:17Z

Importing a new version from external source

New page

{| class="wikitable"
|+ TABLE 2: PHARMACOKINETIC PARAMETERS OF VARIOUS SGLT-2 INHIBITORS
|-
! Name of drug !! Bioavailability !! Protein binding !! tmax (hours) !! t1/2 (hours) !! Cmax !! SGLT2 selectivity over SGLT1
|-
| [[Canagliflozin]] || 65% (300 mg dose) || 99% || 1–2 || 10.6 (100 mg dose); 13.1 (300 mg dose) || 1096 ng/mL (100 mg dose); 3480 ng/mL (300 mg dose) || 250 fold
|-
| [[Dapagliflozin]] || 78% || 91% || 1–1.5 || 12.9 || 79.6 ng/mL (5 mg dose); 165.0 ng/mL (10 mg dose) || 1200 fold
|-
| [[Empagliflozin]] || 90–97% (mice); 89% (dogs); 31% (rats) || 86.20% || 1.5 || 13.2 (10 mg dose); 13.3h (25 mg dose) || 259nmol/L (10 mg dose); 687nmol/L (25 mg dose) || 2500 fold
|-
| [[Ertugliflozin]] || 70-90% || 95% || 0.5-1.5 || 11-17 ||268 ng/mL (15 mg dose) || 2000 fold
|-
| [[Ipragliflozin]] (50 mg) || 90% || 96.30% || 1 || 15–16 (50 mg dose) || 975 ng/mL || 360 fold
|-
| [[Luseogliflozin]] || 35.3% (male rats); 58.2% (female rats); 92.7% (male dogs) || 96.0–96.3% || 0.625±0.354 || 9.24±0.928 || 119±27.0 ng/mL || 1650 fold
|-

Translations:SGLT2 inhibitor/23/en - Revision history

FuzzyBot: Importing a new version from external source